What to expect, and when
The dominant side effects of GLP-1 therapy are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. These are most pronounced during dose escalation — typically the first 4–12 weeks — and tend to attenuate at any given dose after 2–3 weeks of exposure to it.
In the pivotal phase-3 trials, the most common AEs were nausea (in roughly 35–50% of treated patients), diarrhea (10–20%), and vomiting (5–15%). Most events were mild to moderate. Discontinuation due to AEs was in the range of 4–8% across the trials.
Day-to-day GI management
Practical tactics that help most patients:
• Smaller, more frequent meals — large meals are most likely to provoke nausea because the drug slows gastric emptying. • Lower-fat meals during the first few days after each dose escalation — high-fat meals sit in the stomach longer. • Hydration — many patients reduce fluid intake along with food intake, which exacerbates fatigue, dizziness, and constipation. • Plain electrolyte beverages on days when nausea is worst. • Eating early in the day if injection day causes evening nausea.
For constipation: stool softeners (docusate) and bulk fiber (psyllium) are typically first-line. For diarrhea: loperamide for symptomatic relief is acceptable in the absence of fever or bloody stools.
When to slow down dose escalation
If GI symptoms at a given dose persist beyond 2–3 weeks and meaningfully impair your daily function, work with your prescriber to delay the next titration step — or to step back down to the previous dose. There is no clinical advantage to rushing through the titration ladder, and considerable downside in terms of tolerability and adherence.
Most reputable programs build pause-and-step-back logic into their dose-escalation protocols. If your program treats the titration ladder as a fixed automatic schedule, that's worth flagging with your clinician.
Red flags that need clinical attention
Some symptoms warrant prompt clinician contact and may require pausing therapy:
• Severe upper-abdominal pain radiating to the back (possible pancreatitis) • Persistent vomiting that prevents fluid intake (dehydration risk; acute kidney injury risk) • Severe right-upper-quadrant pain (possible gallbladder issues) • Visual disturbances or persistent headaches • Signs of acute kidney injury (decreased urination, swelling, fatigue)
Most programs have a documented escalation pathway for these situations. Knowing how to reach a clinician outside business hours is worth confirming during intake.